Clinical Trial Update: Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating prophylactic Neulapeg (Pegteograstim) in patients with locally advanced or metastatic pancreatic cancer receiving modified FOLFIRINOX.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Neulapeg (Pegteograstim) (pegteograstim)

Snippet

Sponsor: Yonsei University | Conditions: Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 2 | Status: UNKNOWN